Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation

References

• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–7
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–83
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–502
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–7
   PubMed Web of Science ®Google Scholar
• Auner HW, Sill H, Mulabecirovic A, et al. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukaemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374–7
   PubMed Web of Science ®Google Scholar
• Reich G, Mapara MY, Reichardt P, et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–9
   PubMed Web of Science ®Google Scholar
• Straka C, Oduncu F, Hinke A, et al. Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. Blood 2004; 104: 1989–94
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551–73
   PubMed Web of Science ®Google Scholar
• Zambelli A, Montagna D, Da Prada GA, et al. Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res 2002; 22: 3701–8
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A, et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079–87
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–96
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–55
   PubMed Web of Science ®Google Scholar
• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–9
   PubMed Web of Science ®Google Scholar
• Dayyani F, Joeinig A, Ziegler-Heitbrock L, et al. Autologous stem-cell transplantation restores the functional properties of CD14 + CD16+ monocytes in patients with myeloma and lymphoma. J Leukoc Biol 2004; 75: 207–13
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–40
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217–24
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Steidl M, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672–8
   PubMed Web of Science ®Google Scholar
• Steingrimsdottir H, Gruber A, Bjorkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832–8
   PubMed Web of Science ®Google Scholar
• Krause SW, Rothe G, Gnad M, et al. Blood leukocyte subsets and cytokine profile after autologous peripheral blood stem cell transplantation. Ann Hematol 2003; 82: 628–36
   Google Scholar
• Chen BJ, Cui X, Sempowski GD, et al. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004; 103: 4344–52
   PubMed Web of Science ®Google Scholar
• Scheid C, Draube A, Reiser M, et al. Using at least 5×10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999; 23: 1177–81
   PubMed Web of Science ®Google Scholar
• Ashihara E, Shimazaki C, Okano A, et al. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J Clin Oncol 2002; 32: 135–9
   Google Scholar
• Fagnoni FF, Lozza L, Libera C, et al. Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. Bone Marrow Transplant 2003; 31: 31–8
   Google Scholar
• Condomines M, Quittet P, Lu Z-Y, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006; 176: 6631–9
   PubMed Web of Science ®Google Scholar